Serostim - Growth Hormone For Hiv Wasting In Adults - Prior Authorization Form Page 2

Download a blank fillable Serostim - Growth Hormone For Hiv Wasting In Adults - Prior Authorization Form in PDF format just by clicking the "DOWNLOAD PDF" button.

Open the file in any PDF-viewing software. Adobe Reader or any alternative for Windows or MacOS are required to access and complete fillable content.

Complete Serostim - Growth Hormone For Hiv Wasting In Adults - Prior Authorization Form with your personal data - all interactive fields are highlighted in places where you should type, access drop-down lists or select multiple-choice options.

Some fillable PDF-files have the option of saving the completed form that contains your own data for later use or sending it out straight away.

ADVERTISEMENT

CHILDREN’S MEDICAL SERVICES NETWORK
PROTOCOL
®
Serostim
Initial approval period is for a total of ninety (90) days; 30 days for retreatment.
Note: Form must be completed in full. An incomplete form may be returned.
®
Serostim
Criteria:
1. The physician must first complete, sign, and date the Serostim PA form.
2. For initial therapy, or request for additional therapy, the physician must submit official medical records to
support or answer all the questions addressed on the PA form, in addition to a six-month weight chronical
indicating the most recent weights.
3. Recipient must 18 years of age or older.
4. Recipient must have a diagnosis of HIV associated wasting or cachexia.
5. Recipient must be on anti-retroviral therapy.
6. Recipient must have experienced at least a 7.5% unintentional weight loss within the last 6 months, 10%
involuntary weight loss in last 12 months, or have a Body Mass Index (BMI) < 20 for initial approval.
7. Alternatively, recipient may have a Body Cell Mass (BCM) < 35% (male) or <23% (female) of total body
weight and a Body Mass Index less than 27. Another qualifier would be a greater than or equal to 5% BCM
loss over 6 months. (ATTACH A SERIES OF BIOELECTRIC IMPEDANCE ANALYSIS [BIA]
RESULTS IF APPLICABLE.)
8. Treatment must also include nutritional assessment and counseling. Total parenteral nutrition is sometimes of
benefit in patients with damaged gastrointestinal tracts. Appetite stimulants such as megesterol may promote
weight gain; however, most gain with megestrol acetate is in fat rather than BCM.
9. Serostim is contraindicated in patient’s with active neoplasia.
10. Testosterone replacement therapy (minimum of 4 weeks) in hypogonadal men may increase lean body mass
and muscle strength.
11. Oxandrolone has been found to produce significant increases in weight gain and BCM.
12. Dosage must be adjusted according to recipient’s weight.
Weight Range
Dose
>55kg (121 lb)
6 mg SC daily
45-55kg (99-121 lb)
5 mg SC daily
35-45kg (75-99 lb)
4 mg SC daily
<35 kg(<75 lb)
0.1 mg/kg SC daily
13. Length of therapy is 12 weeks; however, if a positive response to therapy (a 2% or greater increase in body
weight and/or BCM) occurs but wasting is still evident, treatment may be continued and response reevaluated
on a month-by-month basis. THEREFORE, RETREATMENT WILL BE APPROVED FOR A
MAXIMUM OF 30 DAYS AT A TIME.
14. Physician must submit a new PA form for additional therapy.
Page 2

ADVERTISEMENT

00 votes

Related Articles

Related forms

Related Categories

Parent category: Medical
Go
Page of 2